Page 324 - Drug Class Review

Drug Effectiveness Review Project
rivastigmine (6-12 mg/d) 73.8 68 97% 3% 0% 19.62 47% Page 192 of 205

Groups similar at baseline: No (more females in high dose RIV group)

rivastigmine (1-4 mg/d) 74.9 57 95% 4% 1% 19.5 47% Primary Outcome Measures: ADAS-Cog; CIBIC-plus; PDS (all stratified by baseline MHIS score Secondary Outcome Measures: MMSE; GDS (all stratified by baseline MHIS score category) Timing of assessments: Baseline, and weeks 12, 18 and 26 or early termination Treatment differences in PDS scores between high dose RIV and placebo were greater in the MHIS > 0 group than the MHIS = 0 group (5.9 vs 3.5) Treatment differences in ADAS-Cog scores between RIV 6-12 mg/d and placebo greater in the MHIS > 0 group than the MH

Alzheimer classification: Mild-moderate

Health Outcome Measures:

placebo 74.8 58 94% 4% 2% 20 44% category; MHIS > 0 means VRF are present) Intermediate Outcome Measures:

• • • • •

Final Report Update 1 Authors: Kumar et al. Year: 2000 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Other • Other germane population qualities: Mean MMSE score • % with MHIS > 0 (VRF) • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs